Cyramza Injection
Ramucirumab
10mg/ml
ELI LILLY AND COMPANY
| Pack size | 50ml Glass Vial |
|---|---|
| Dispensing mode | POM |
| Source | USA |
| Agent | PHARMATRADE |
| Retail Price | 21477.50 AED |
Available as:
Indications
Cyramza Injection is used for:
For use in advanced gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing chemotherapy.
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Ramucirumab :
Mechanism of Action
Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation, permeability, and migration of human endothelial cells.
Note
Cyramza 10mg/ml Injection manufactured by ELI LILLY AND COMPANY. Its generic name is Ramucirumab. Cyramza is availble in United Arab Emirates.
Farmaco UAE drug index information on Cyramza Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.